Αρχική World News Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as... World News Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone Από Ogkologos - 24 Ιουνίου, 2025 1040 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR One year on: How has COVID-19 affected cancer services? 14 Μαΐου, 2021 How to Find the Right Hospice Care Program for You or... 10 Αυγούστου, 2023 Father Dances With Joy After Learning His Son Is Cancer Free 14 Νοεμβρίου, 2021 How targeted screening can help the NHS save lives from lung... 23 Νοεμβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... COVID-19: “It could take months to build research up again”